Lisata Therapeutics Inc. – Material Contracts Watch

EX-10.1

from 8-K 4 pages James Nisco Re: Retention Bonus Opportunity Dear James: We Are Pleased to Inform You That, in Recognition of Your Contributions to Lisata Therapeutics, Inc. (The “Company”), You Are Being Offered the Opportunity to Receive a Retention Bonus (The “Retention Bonus”) on the Following Terms and Conditions

12/34/56

EX-10.1

from 8-K 23 pages Contingent Value Rights Agreement

12/34/56

EX-10.19

from 10-K 36 pages Material contract

12/34/56

EX-10.18

from 10-K 53 pages David J. Mazzo, Phd President & CEO Mark Land CEO David J. Mazzo, Phd President & CEO Mark Land CEO

12/34/56

EX-10.5

from 10-K 38 pages Material contract

12/34/56

EX-10.2

from 10-K 18 pages Material contract

12/34/56

EX-10.1

from 8-K 3 pages [Signature Page to Amendment to Binding Term Sheet] in Witness Whereof, the Parties to This Amendment Have Caused Same to Be Executed as of the Date First Written Above. Lisata Therapeutics, Inc. By: Name: David J. Mazzo, PH.D. Title: President and CEO Kuva Labs Inc. By: Name: Mark Land Title: CEO

12/34/56

EX-10.4

from 10-Q 9 pages Material contract

12/34/56

EX-10.3

from 10-Q 9 pages Material contract

12/34/56

EX-10.2

from 10-Q 21 pages Material contract

12/34/56

EX-10.1

from 10-Q 16 pages Material contract

12/34/56

EX-10.4

from 8-K 9 pages Material contract

12/34/56

EX-10.3

from 8-K 9 pages Material contract

12/34/56

EX-10.2

from 8-K 21 pages Material contract

12/34/56

EX-10.1

from 8-K 16 pages Material contract

12/34/56

EX-10.14

from 10-K 53 pages David J. Mazzo, Phd President & CEO Mark Land CEO David J. Mazzo, Phd President & CEO Mark Land CEO

12/34/56

EX-10.5

from 10-K 38 pages Material contract

12/34/56

EX-10.2

from 10-K 103 pages Material contract

12/34/56

EX-10.5

from 10-K 30 pages Material contract

12/34/56

EX-10.2

from 10-K 86 pages Material contract

12/34/56